|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 144.20 USD | +2.75% |
|
+4.13% | +47.52% |
| 28/07 | Former FDA chief says Central Mexico may have broad cyclosporiasis contamination | RE |
| 23/07 | How the hunt for value sparked a U.S. private-label revolution | RE |
Company Valuation: Target Corporation
Data adjusted to current consolidation scope
| Fiscal Period: January | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 105,613 | 79,238 | 64,208 | 63,192 | 47,757 | 63,741 | - | - |
| Change | - | -24.97% | -18.97% | -1.58% | -24.42% | 33.47% | - | - |
| Enterprise Value (EV) 1 | 113,422 | 93,148 | 76,441 | 74,370 | 58,725 | 76,265 | 76,252 | 76,254 |
| Change | - | -17.88% | -17.94% | -2.71% | -21.04% | 29.87% | -0.02% | 0% |
| P/E | 15.6x | 28.8x | 15.6x | 15.6x | 13x | 17x | 16x | 15.2x |
| PBR | 8.1x | 7.06x | 4.78x | 4.28x | 2.95x | 3.69x | 3.42x | 3.19x |
| PEG | - | -0.5x | 0.3x | -17.43x | -1.58x | 9.33x | 2.66x | 2.9x |
| Capitalization / Revenue | 1x | 0.73x | 0.6x | 0.59x | 0.46x | 0.59x | 0.57x | 0.55x |
| EV / Revenue | 1.07x | 0.85x | 0.71x | 0.7x | 0.56x | 0.7x | 0.68x | 0.66x |
| EV / EBITDA | 9.48x | 14.1x | 8.89x | 8.59x | 7.43x | 8.97x | 8.56x | 8.15x |
| EV / EBIT | 12.2x | 23.9x | 13.4x | 13.4x | 12.3x | 14.3x | 13.6x | 12.6x |
| EV / FCF | 22.3x | -61.7x | 20x | 16.6x | 20.7x | 37.1x | 28.6x | 26.5x |
| FCF Yield | 4.48% | -1.62% | 4.99% | 6.02% | 4.83% | 2.7% | 3.5% | 3.77% |
| Dividend per Share 2 | 3.38 | 4.14 | 4.38 | 4.46 | 4.54 | 4.55 | 4.526 | 4.955 |
| Rate of return | 1.53% | 2.41% | 3.15% | 3.23% | 4.3% | 3.24% | 3.22% | 3.53% |
| EPS 2 | 14.1 | 5.98 | 8.94 | 8.86 | 8.13 | 8.278 | 8.777 | 9.237 |
| Distribution rate | 24% | 69.2% | 49% | 50.3% | 55.8% | 55% | 51.6% | 53.6% |
| Net sales 1 | 106,005 | 109,120 | 107,412 | 106,566 | 104,780 | 108,898 | 112,088 | 115,450 |
| EBITDA 1 | 11,970 | 6,596 | 8,600 | 8,653 | 7,909 | 8,503 | 8,903 | 9,354 |
| EBIT 1 | 9,328 | 3,896 | 5,707 | 5,566 | 4,775 | 5,332 | 5,616 | 6,032 |
| Net income 1 | 6,946 | 2,780 | 4,138 | 4,091 | 3,705 | 3,758 | 3,956 | 4,109 |
| Net Debt 1 | 7,809 | 13,910 | 12,233 | 11,178 | 10,968 | 12,523 | 12,511 | 12,513 |
| Reference price 2 | 220.43 | 172.14 | 139.08 | 137.91 | 105.47 | 140.34 | 140.34 | 140.34 |
| Nbr of stocks (in thousands) | 479,124 | 460,310 | 461,662 | 458,212 | 452,806 | 454,191 | - | - |
| Announcement Date | 1/3/22 | 28/2/23 | 5/3/24 | 4/3/25 | 3/3/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 16.95x | 0.7x | 8.97x | 3.24% | 63.74B | |
| 46.22x | 1.36x | 28.6x | 0.56% | 422B | |
| 15.75x | 0.84x | 8.28x | 3.14% | 47.75B | |
| 36.27x | 6.79x | 21.21x | 0.25% | 35.9B | |
| 16.71x | 0.67x | 8.57x | 1.93% | 27.18B | |
| 23.4x | 1.17x | 12.65x | 0.97% | 16.33B | |
| 16.86x | 1.59x | 7.73x | 1.47% | 6.48B | |
| 15.64x | 0.53x | 7.88x | 4.56% | 4.59B | |
| 14.84x | 1.21x | 8.7x | -.--% | 4.04B | |
| 10.35x | 0.72x | 5.76x | 4.56% | 2.93B | |
| Average | 21.30x | 1.56x | 11.83x | 2.07% | 63.09B | |
| Weighted average by Cap. | 37.64x | 1.52x | 22.78x | 1.13% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- TGT Stock
- Valuation Target Corporation
Select your edition
All financial news and data tailored to specific country editions
